⌘K
Loading ticker…
As of 2026-08-24, Intellia Therapeutics, Inc (NTLA) has a 3-month relative strength percentile of 47 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 53. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.2%, relative volume 0.88×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
NTLA is held by 28 ETFs as of May 2026. Top owner: SCHA at 0.04% weight, $9M notional. Top 3 carry $22M.
Held by 69 ETFs · $467M across latest filings · largest weight 3.82% (ARKG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.04% | $9M | — |
| VTWO | 0.05% | $8M | — |
| VHTVanguard Health Care ETF | 0.03% | $5M | — |
| AVSC | 0.10% | $3M | +0.01 pp |
| VTWV | 0.10% | $1M | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $978K |
| — |
| GNOM | 1.59% | $888K | +0.41 pp |
| FSCC | 0.24% | $669K | new |
| ONEQ | 0.01% | $576K | — |
| VFMO | 0.03% | $561K | new |
Showing 10 of 28 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NTLA Jan avg: 8.64% median: 5.07% win: 50% σ: 31.21% n: 4 2022-04-12 → 2026-07-31 | NTLA Feb avg: 8.02% median: 1.28% win: 50% σ: 18.38% n: 4 2022-04-12 → 2026-07-31 | NTLA Mar avg: -14.52% median: -10.79% win: 0% σ: 10.58% n: 4 2022-04-12 → 2026-07-31 | NTLA Apr avg: -2.30% median: 1.29% win: 60% σ: 19.54% n: 5 2022-04-12 → 2026-07-31 | NTLA May avg: -5.09% median: -1.30% win: 20% σ: 10.42% n: 5 2022-04-12 → 2026-07-31 | NTLA Jun avg: 16.62% median: 12.18% win: 100% σ: 12.49% n: 5 2022-04-12 → 2026-07-31 | NTLA Jul avg: 6.65% median: 17.11% win: 80% σ: 25.78% n: 5 2022-04-12 → 2026-07-31 | NTLA Aug avg: -8.89% median: -9.36% win: 0% σ: 5.19% n: 4 2022-04-12 → 2026-07-31 (current) | NTLA Sep avg: 5.30% median: -7.62% win: 25% σ: 31.43% n: 4 2022-04-12 → 2026-07-31 | NTLA Oct avg: -21.05% median: -23.85% win: 0% σ: 11.04% n: 4 2022-04-12 → 2026-07-31 | NTLA Nov avg: -0.78% median: 3.67% win: 50% σ: 20.51% n: 4 2022-04-12 → 2026-07-31 | NTLA Dec avg: -13.66% median: -12.68% win: 25% σ: 17.71% n: 4 2022-04-12 → 2026-07-31 |